Ajaypal Singh to Prolyl-Hydroxylase Inhibitors
This is a "connection" page, showing publications Ajaypal Singh has written about Prolyl-Hydroxylase Inhibitors.
Connection Strength
2.699
-
The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
Score: 0.892
-
Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO. Am J Nephrol. 2022; 53(5):361-365.
Score: 0.862
-
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019 11; 28(6):600-606.
Score: 0.726
-
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
Score: 0.220